Kornimate/medical-research-clean huggingface dataset:
prospective collection of pillcam sb3 videos and raw data files for future developments (soda)

Conditions: Small Intestine Disease; Small Intestine Cancer; Small Intestinal Ulcer Bleeding; Small Intestine Obstruction; Small Intestine Adenocarcinoma; Small Intestine Polyp

Summary: observational, multicenter, post-market, minimal risk, prospective data collection of pillcam sb3 videos (including pillcam reports) and raw data files and optional collection of eneteroscopy reports

up to 8000 pillcam sb3 videos (including pillcam reports) and raw data files will be collected in up to 50 medical centers in the us. study duration is up to 7 years from irb approval. medical center study sites will provide relevant videos (including pillcam reports) and raw data from patients who underwent sb3 procedures. per patient demographic data will be also collected to provide a description of the study population characteristics and disposition. additional standard of care data collection might be performed (optional). this data will include a de-identified eneteroscopy report, from patients enrolled to the study and referred to eneteroscopy procedure (all types of eneteroscopies), following findings identified during the pillcamtm sb procedure, as part of the standard of care procedure. this data might be collected retrospectively for enrolled patients who underwent an eneteroscopy procedure. the de-identified reports will be used by mdt gi research and development team to further develop and validated sb capsule localization. study subjects will not undergo any additional procedures, nor will their diagnosis and subsequent treatment pathway be changed for the purpose of the registry. the data will be used by mdt gis research and development team for the development and validation of improved and new detectors in the pillcam software. the videos (including pillcam reports) and raw data files will be de-identified at the medical center by representatives who are authorized and delegated to review medical records, prior to providing them to the sponsor. all data in the study- videos, reports, raw data files and demographic information will be de-identified in a manner that is untraceable by the sponsor clinical study team members.

Eligibility criteria:
inclusion criteria: * all sb3 cases collected during standard of care procedures. * the subject received an explanation and understands the nature of the study and provided oral consenting exclusion criteria: * none
ambulatory assessment of motor state in patients with parkinson's disease in real daily life

Conditions: Parkinson's Disease

Summary: patients with parkinson's disease (pd) suffer from motor fluctuations and levodopa induced dyskinesia. the prupose of this study is to evaluate the effect of an automatic system to assess the motor state of pd patients in real daily life. movements and postures are assessed using 6 accelerometers attached to the the most affected wrist, trunk, both upper legs and both upper arms. patients wear the system for two days and keep an own diary of their motor state


Eligibility criteria:
inclusion criteria: patients with parkinson's disease with motor fluctuations and dyskinesias exclusion criteria:
low back pain patient education evaluation

Conditions: Low Back Pain

Summary: back pain is one of the most common of all symptoms. it is also a great cause of days lost from work and visits to health care providers. this study will develop and evaluate an approach to low back pain that allows subjects to talk with each other and with health professionals via an internet discussion group. results we will look at include health behaviors, such as exercise; health status, such as pain and disability; and health care use, such as number of visits to doctors and other health care providers. anyone 18 years old or older who lives in the united states and has ongoing internet access can take part in the study. all subjects must have back pain and meet the eligibility criteria listed below.

this study will develop and evaluate in a randomized trial a low back pain intervention that allows subjects to talk with each other and with health professionals via an internet discussion group. the intervention consists of a book and a videotape and is based on interaction with other participants in the program and health professionals through a closed password protected moderated internet discussion group. outcome measures include health behaviors, such as exercise; health status, such as pain and disability; and health care use, such as number of visits to doctors and other health care providers. patients will be randomized either to the treatment group and followed for 6, 12, 18, and 24 months with the intervention.

Eligibility criteria:
inclusion criteria: * must live in the united states * must understand and write english * must have access to a computer with e-mail and expect to have this access for at least 3 years * must be 18 years old * must have seen a doctor for back pain at least once in the past year exclusion criteria: * pregnancy * back surgery in the past 6 months * expectation of having back surgery in the next 6 months * back pain due to a car accident or other major injury within the last 6 months * back pain or sciatica due to systemic disease (inflammatory rheumatic diseases, tumor, or other) * major physical or mental health condition for which one is currently being treated that severely limits daily activities * terminal illness * receiving disability or workers compensation insurance payments for back pain or sciatica * presently involved in legal proceedings because of back pain or sciatica * difficulty with bladder or bowel control that began with back pain or sciatica * no visits to a doctor in the past year for back pain or sciatica * numbness in crotch area that began with back pain or sciatica * age under 18

Keywords: health education back injury chronic pain education/evaluation planning outcomes research
liraglutide as additional treatment to insulin in patients with autoimmune diabetes mellitus

Conditions: Type 1 Diabetes Mellitus; Autoimmune Diabetes

Summary: the purpose of this study is to investigate the therapeutic effect of liraglutide on autoimmune diabetes.

autoimmune diabetes mellitus (aidm) is a subtype of diabetes mellitus caused by autoimmune destruction of beta cells in the islet, including type 1 diabetes and latent autoimmune diabetes in adults (lada). insulin has been used as a routine therapy for aidm to alleviate the hyperglycemic status, yet cannot effectively prevent the progressing destruction of beta cells or preserve its function. glucagon-like peptide (glp-1) analog liraglutide has been tested in large-scale clinical trial to prove its various benefits for beta cells and glucolipid metabolism in type 2 diabetes and obesity patients. however, its clinical application in aidm is not well-defined so far. the aim of this study is to investigate the potential use of liraglutide on glycemic control in aidm.

Eligibility criteria:
inclusion criteria: * type 1 diabetes according to ada criteria \<3 years. * age≥ 18 years. * positive for at least one of the anti-islet autoantibodies: gada, ia2a, znt8a * fasting or postprandial plasma c-peptide more than 100 pmol/l * written informed consent from the patient or family representative exclusion criteria: * history or family history of medullary thyroid carcinoma or men 2 syndrome; * history of chronic or acute pancreatitis; * allergic to liraglutide or any components in victoza®; * hepatic abnormalities (transaminase \> 2 times normal); * renal impairments (serum creatinine \>133 umol/l); * cardiovascular diseases (hypertension, coronary heart disease, etc.); * presence of acute metabolic disorders; in the case of acute ketone acidosis, with blood ketone over 0.3mmol/l and ph lower than 7.30; * any history of malignancy; * female patients who are pregnant or breastfeeding; any female who is unwilling to use a reliable and effective form of contraception for 2 years after recruitment; * presence of any infectious diseases, including active skin infections, flu, fever, upper or lower respiratory tract infections; those who wish to participate in the study should keep the infection under control for at least 1 week before receiving treg product infusion; * any medical condition that, in the opinion of the investigator, will interfere with safe participation in the trial.
effect of hyperuricaemia on chronic renal disease

Conditions: Hyperuricemia; Chronic Renal Disease

Summary: to investigate the effect of hyperuricaemia on chronic renal disease and intervention

this study aims to explore the best effective dose and adverse reaction of febuxostat in lowering serum uric acid to low level in patients with chronic renal disease at different stages. to elucidate that low levels of serum uric acid can delay the progression of renal damage. promote the application of anti uric acid drugs in the treatment of chronic renal failure and delay the progress of ckd in patients

Eligibility criteria:
inclusion criteria: * non-dialysis ckd patients with serum uric acid greater than 7mg/dl. * egfr≥15ml/min/1.73m². * low salt, low protein, low purine diet. exclusion criteria: * take drugs that raise blood uric acid at the same time. * patients with gout attacks. * patients with pregnant, lactating. * autosomal dominant polycystic kidney disease. * patients with poor general condition and multiple organ failure.

Keywords: uric acid febuxostat chronic renal disease
adaptive interventions for problem drinkers

Conditions: Alcohol-Related Disorders; Alcohol Use Disorders; Alcohol Drinking; Alcoholism; Alcohol Abuse

Summary: the purpose of this study is to understand how certain interventions help people reduce or quit their drinking and how certain interventions may help best at certain points in time in the change process.

problem drinkers (pds) represent a majority of the estimated 32 million americans with alcohol problems that spans a spectrum of severity from individuals who drink excessively and experience of occasional negative consequences to those with moderate alcohol dependence (ad) and intact psychosocial functioning. pds can benefit from relatively brief treatment that could be delivered in mainstream healthcare, but less than 5% receive such care. in addition, pd treatment is only modestly effective, and there is a surprising absence of empirical research to guide pd treatment selection. adaptive interventions (ai) are a novel approach to treatment development that may have significant advantages over fixed treatments in improving efficacy and fostering adoption of evidence based practices in mainstream healthcare. if study aims are achieved, a set of empirically-derived decision support tools will be created to guide alcohol use disorders (aud) care similar to tools that exist for other chronic diseases. in addition, new knowledge will be gained about mechanisms of behavior change of aud that can guide future aud treatment research. finally, important progress will be made in methods that capitalize on the remarkable advances in sensor technologies, advanced mathematics, and engineering to create a new type of tailored, near-real time feedback, adaptive behavior therapies.

Eligibility criteria:
primary inclusion criteria: adults who have heavy weekly alcohol consumption (and/or an alcohol use disorder) and are willing to reduce their drinking. primary exclusion criteria: adults for whom the level of treatment provided is not appropriate and/or who require more intensive substance use or psychiatric treatment.

Keywords: drinking alcohol problems alcoholism reduced drinking problematic drinking non-abstinence-based drinking controlled drinking heavy drinking
effect of cough assist device in copd patients admitted to respiratory intensive care unit at assiut university hospital

Conditions: COPD Exacerbation

Summary: 1. to evaluate the effecacy of cough assist device (cad) in copd patients admitted in ricu either on invasive or non-invasive ventilation. 2. to detect any possible complications associated with the use of cough assist device.

effective cough is a protective mechanism against respiratory tract infections. copd patients may have impaired cough and a reduction in peak cough flows(pcf) as a result of inspiratory and expiratory muscle weakness, which causes a reduction in the pressure available to drive the cough manoeuver. cough augmentation with mechanical insufflation-exsufflation (mi-e) has been described as a technique that facilitates airway secretion clearance in copd patients, thus avoiding hospitalisations and preventing pneumonias and episodes of respiratory failure . cough augmentation techniques comprise lung volume recruitment, (also termed air stacking or breaths tacking), mechanically assisted cough using mechanical insufflation-exsufflation (mi-e) device. during lung volume recruitment, the person inhales a volume of gas via the ventilator, or self-inflating resuscitation bag adapted with a one-way valve to facilitate gas holding. the person retains the inhaled volume by closing the glottis, inhales another volume of gas and then again closes the glottis; this process is repeated until maximum insufflation capacity is reached mi-e devices deliver a positive (inflation) and negative pressure (rapid deflation) delivered to the person via an oronasal interface, mouthpiece, or endotracheal or tracheostomy tube. mi-e comprises a pressure -targeted lung insufflation followed by vacuum exsufflation, enabling lung emptying and increasing peak cough flow. alternation of pressure may be manually or automatically cycled. pressures of 40 mmhg (insufflation) to 40 mmhg (exsufflation) (54 cmh2o) are usually most effective and best tolerated by the person . treatments usually comprise three to five insufflation-exsuflation cycles followed by a short period of rest to avoid hyperventilation. treatments can be repeated until no further secretions are expectorated. mie can be performed in isolation or in combination with manually assisted cough . few complications associated with mi-e devices as a drop in oxygen levels, barotrauma elevated blood pressure for more than 30 minutes have been reported, most likely due to use of pressures that are much lower than physiological cough pressures and the short duration of application .

Eligibility criteria:
inclusion criteria: * all copd patients above 18 years old who admitted to ricu. exclusion criteria: * • all patients who have: neuromuscular diseases, pulmonary oedema, cardiac arrest, cardiogenic shock, acute myocardial infarction, pneumothorax, pulmonary neoplasm, pulmonary thromboembolism.
vivatmo pro™ for fractional exhaled nitric oxide (feno) monitoring in u.s. asthmatic patients

Conditions: Asthma; Asthma in Children

Summary: this is a multi-center study to evaluate fractional exhaled nitric oxide (feno) measured with the vivatmo pro in adult and pediatric subjects.

subjects will be screened, enrolled and tested at study visit #1 and then prescribed inhaled corticosteroid (ics) treatment as per routine clinical care. subjects will return for study visit #2 in two weeks and repeat fractional exhaled nitric oxide (feno) measured with the vivatmo pro

Eligibility criteria:
inclusion criteria: 1. subject is 7 to 80 years of age. 2. has asthma 3. has been identified as a candidate for inhaled corticosteroid (ics) treatment 4. is willing and able to perform vivatmo pro™ testing exclusion criteria: 1. subject has used corticosteroids prior to enrollment. 2. subject has other current serious medical conditions 3. subject has not been clinically stable for at least 2 weeks prior to the study 4. subject is unwilling or unable to perform vivatmo pro testing
covid-19: a pilot study of adaptive immunity and anti-pd1

Conditions: COVID-19; SARS-CoV-2; 2019-nCoV; Pneumonia, Viral

Summary: this is an open-label, controlled, single-centre pilot study of nivolumab in adult patients with covid-19. this clinical study aims to evaluate efficacy of anti-pd1 antibody in relation to viral clearance and its safety.


Eligibility criteria:
inclusion criteria: * diagnosis of covid-19 by rt-pcr for sars-cov-2 * clinically stable with disease severity defined as mild or moderate (mild disease is defined as symptoms with or without lung infiltrates on chest x-ray or ct imaging; moderate disease is defined as lung infiltrates with evidence of type 1 respiratory failure) * asymptomatic patients may be enrolled if patients have obvious radiographic changes on chest or ct radiography deemed to be related to covid-19 exclusion criteria: * active cancer, rheumatological and autoimmune conditions * transplant recipients, or patients on active immunosuppressants * chronic organ impairment, or documented or suspected concomitant infections (including chronic viral hepatitis b and hepatitis c) other than sars-cov-2 * lactating mothers and women who are pregnant or intending to become pregnant * acute respiratory distress syndrome, evidence of myocardial injury, disseminated intravascular coagulopathy, organ failure, hemophagocytosis, shock, respiratory distress, or need for mechanical ventilation, aicu admission, or high flow oxygen therapy

Keywords: covid-19 sars-cov-2 2019-ncov coronavirus anti-pd1 nivolumab
study of sgi-1776, a pim kinase inhibitor, in subjects with relapsed/refractory leukemias

Conditions: Relapsed/Refractory Leukemias

Summary: dose escalation study for subjects with leukemia that has returned or has not responded to standard treatment.

a phase 1, multicenter, open-label, dose-escalation study of sgi-1776, a pim kinase inhibitor, in subjects with relapsed/refractory leukemias

Eligibility criteria:
inclusion criteria: 1. men and women with a confirmed diagnosis of leukemia unresponsive to curative therapy 2. eastern cooperative oncology group performance status of 0 to 2 3. total bilirubin ≤ 1.5 x upper limit of normal (uln); aspartate transaminase (ast/sgot) and alanine transaminase (alt/sgpt) ≤ 3 x uln; serum creatinine ≤ 2 x uln 4. normal cardiac function with left ventricular ejection fraction ≥ 50% at screening 5. no clinically significant abnormalities on screening electrocardiogram (ie, qtc interval must be \< 470 msec for women and \< 450 msec for men and no history of torsades de pointes) 6. no reproductive potential or willing to use 2 methods of contraception during the study and for 30 days after the last dose 7. able to understand the purpose and risks of the study and provide informed consent and authorization to use protected health information exclusion criteria: 1. a life-threatening illness, medical condition or organ system dysfunction which, in the investigator's opinion, could compromise the subject's safety, interfere with the absorption or metabolism of oral sgi-1776, or put the study outcomes at undue risk 2. significant cardiovascular disease 3. malabsorption syndrome 4. symptomatic central nervous system metastases or lesions for which treatment is required 5. received prior radiation therapy within 4 weeks of first dose 6. grade ≥ 2 toxicity (other than alopecia) continuing from prior anticancer therapy including radiation 7. treatment with any investigational drug within 3 weeks of the first dose 8. use of systemic corticosteroids (other than for premedications or intermittent doses such as those used for allergic reactions and control of asthma) or myelosuppressive chemotherapy within 2 weeks of the first dose treatment with nitrosoureas or mitomycin c within 3 weeks of the first dose of sgi 1776 9. uncontrolled active systemic infections
study of edecesertib in participants with cutaneous lupus erythematosus (cle)

Conditions: Cutaneous Lupus Erythematosus (CLE)

Summary: the goal of this clinical study is to test how edecesertib (formerly known as gs-5718) can be useful in treating cutaneous lupus erythematosus (cle) in participants with cle. information on what is happening in the body relating to cle, how the body processes, is affected by and responds to the study drug, and any study drug side effects will also be collected in this study.


Eligibility criteria:
key inclusion criteria: * either fulfill european league against rheumatism/american college of rheumatology (eular/acr) 2019 classification criteria for systemic lupus erythematosus (sle) and/or have biopsy confirmed cutaneous lupus erythematosus (cle) at any time. * must have active cle at screening and day 1. individuals with acute cle (acle) must have involvement of 2 distinct body areas. * cutaneous lupus erythematosus disease area and severity index activity - a (clasi-a) score (excluding alopecia) of ≥ 8 and clasi-a erythema score of ≥ 4 during screening and on day 1. individuals with sle must have systemic lupus erythematosus disease activity index 2000 (sledai-2k) score of ≥ 4 at screening. * presence of at least 1 representative lupus skin lesion amenable to punch biopsy and individual willingness to undergo skin punch biopsy at 2 time points. * must have documented prior intolerance or inadequate response at any time (per investigator judgement) to protocol-specified treatments. * topical corticosteroids or topical calcineurin inhibitors. * oral corticosteroids. * any other nonbiologic standard-of-care therapy, including, but not limited to: chloroquine, quinacrine, hydroxychloroquine, azathioprine, mycophenolate mofetil (mmf), leflunomide, dapsone, or methotrexate (mtx). * individuals willing to comply with all study visits and assessments. key exclusion criteria: * individuals with only chilblains lupus, lupus panniculitis, lupus tumidus and/or localized acute cle involving only 1 distinct body area at screening and day 1. * have highly active sle (including but not limited to lupus nephritis, neuropsychiatric sle, and/or vasculitis). * presence of active skin conditions other than cutaneous lupus that may interfere with assessing lupus-specific skin lesion(s) (eg, psoriasis, and/or drug-induced lupus). * meet protocol-specified infection or lab criteria. * any active infection that is clinically significant (per investigator judgment). * any history of clinically significant liver disease. * significant cardiovascular disease. note: other protocol defined inclusion/exclusion criteria may apply.